Gene therapy of hemoglobinopathies: progress and future challenges

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia are genetic blood disorders.
• Gene therapy has emerged as a potential curative approach for these conditions.
• Key discoveries include the β-globin locus control region and its role in gene expression.

Purpose of the Study:

• To review current gene therapy strategies for hemoglobinopathies.
• To summarize ongoing clinical trials and their outcomes.
• To discuss challenges and future directions for gene therapy in SCD and β-thalassemia.

Main Methods:

• Utilizing lentiviral vectors for gene insertion into hematopoietic stem cells.
• Employing genome editing techniques to correct mutations or restore fetal hemoglobin.
• Analyzing data from recent clinical trials for β-thalassemia and SCD.

Main Results:

• Gene therapy has shown promising outcomes in clinical trials, reducing or eliminating transfusion needs for patients.
• Lentiviral vectors demonstrate efficient gene transfer with safe integration profiles.
• Genome editing offers alternative strategies for disease correction.

Conclusions:

• Gene therapy holds significant potential for treating SCD and β-thalassemia.
• Reducing toxic myeloablation and high costs are crucial for widespread clinical application.
• Further research is needed to optimize gene therapy platforms and improve accessibility.